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Abstract: We report a case of severe diabetic macular edema (DME) that developed after 
pioglitazone was used by a patient with proliferative diabetic retinopathy. A 30-year-old woman 
with poorly controlled type 2 diabetes mellitus visited our clinic in 2004. She had moderate 
pre-proliferative diabetic retinopathy OU. Because of the rapid progression of the diabetic 
retinopathy, she received pan-retinal photocoagulation in both eyes. Two weeks before using 
pioglitazone, her visual acuity was 0.9 OD and 0.7 OS. On October 2007, pioglitazone was 
prescribed by her internist because of poorly controlled blood glucose level. Two weeks later, her 
body weight increased, and her face became edematous. Her visual acuity decreased to 0.5 OU, 
and ophthlamoscopy showed severe DME in both eyes. Two weeks after stopping pioglitazone, 
her visual acuity improved to 0.8 OD and 0.5 OS, but the DME was still severe in the optical 
coherence tomographic images. Then, one half the usual dose (25 mg) of spironolactone, a 
diuretic, was given and her macular edema was resolved. Her ﬁ  nal visual acuity improved to 0.9 
OD and 0.7 OS. We recommend that when a patient taking pioglitazone complains of decreased 
vision, the physician should promptly consult an ophthalmologist.
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Introduction
Pioglitazone, a thiazolidinedione agent, is prescribed to diabetic patients to reduce 
insulin resistance (Aronoff et al 2000; Herz et al 2003). A recent meta-analysis 
showed that pioglitazone reduces the risk of cardiovascular events in patients 
with type 2 diabetes mellitus (DM) (Lincoff et al 2007). Thus, pioglitazone has 
become one of the major drugs prescribed for the primary care for patients with 
type 2 DM.
Pioglitazone can cause ﬂ  uid retention and peripheral edema in diabetic patients 
(Niemeyer and Janney 2002; Mudaliar et al 2003), and the systematic ﬂ  uid retention 
can be manifested as diabetic macular edema (DME) (Perkovich and Meyers 1988; 
Tokuyama et al 2000). However, one report has indicated the adverse effect of 
pioglitazone on DME in patients with type 2 DM (Ryan et al 2006). We report a case of 
severe DME that developed after pioglitazone was used by a patient with proliferative 
diabetic retinopathy. In this case, the DME resolved with cessation of the pioglitazone 
and the use of a diuretic.
Case report
A 30-year-old woman visited our clinic for examination of her diabetic retinopathy 
in 2004. She was a type 2 diabetic and had moderate nonproliferative diabetic 
retinopathy with a glycosylated hemoglobin A1c (HbA1c) of 12%. No treatment 
was given, but during the follow-up period her retinopathy worsened and pan-retinal Vascular Health and Risk Management 2008:4(5) 1138
Oshitari et al
photocoagulation was applied to both eyes; the left eye had 
pan-retinal photocoagulation in 2004 with 1700 burns, and 
the right eye had pan-retinal photocoagulation in 2006 with 
2000 burns. Although mild vitreous hemorrhage developed 
in both eyes during the pan-retinal photocoagulation, the 
retinopathy became stable with proliferative tissues sur-
rounding the optic disc in both eyes (Figures 1 and 2). 
DME did not develop during and immediately after the 
pan-retinal photocoagulation in both eyes.
Her best corrected visual acuity was 0.9 OD and 0.7 
OS 2 weeks before using pioglitazone, and DME was not 
present before the pioglitazone treatment (Figures 1, 2, 
3A). She had been prescribed 3 drugs for controlling the 
hyperglycemia before taking pioglitazone. No drugs other 
than pioglitazone were prescribed after the cessation of 
pioglitazone.
Two weeks after taking pioglitazone, she visited our 
clinic. Her face was edematous, and she had gained weight 
(Table 1). Optical coherence tomography (OCT) showed 
that she had severe DME in both eyes, and a serous retinal 
detachment in the right eye (Figure 3B). Her visual acuity 
was decreased to 0.5 OU. We recommended that she ask 
her primary physician to stop the pioglitazone; however, 
pioglitazone could not be stopped because there had been 
no reports in Japan of any adverse effect of pioglitazone on 
developing DME and the HbA1c level was still high.
One month later, her DME and serous retinal detach-
ment worsened (Figure 3C). We explained our ﬁ  ndings to 
the primary physician and suggested that if possible, pio-
glitazone be stopped. He kindly cooperated and agreed to 
stop the pioglitazone. Two weeks later, her vision improved 
to 0.8 OD and 0.5 OS. However, the severe DME was still 
present in the right eye in the OCT images (Figure 3D). 
We then prescribed 25 mg of spironolactone, a diuretic, 
which is one half the usual dose for reducing ﬂ  uid retention 
and peripheral (facial) edema. Two months later, her body 
weight was reduced by 8 kg (Table 1), and her DME was 
signiﬁ  cantly reduced in both eyes (Figure 3E). Her ﬁ  nal 
visual acuity returned to 0.9 OD and 0.7 OS.
Discussion
Fluid retention and peripheral edema develop in 10% of 
patients using pioglitazone (Niemeyer and Janney 2002; 
Mudaliar et al 2003). Because systematic ﬂ  uid retention can 
aggravate DME (Perkovich and Meyers 1988; Tokuyama et al 
2000), the vision of patients with DME using pioglitazone 
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Figure 1 Fundus photographs before and after pioglitazone treatment. A and B: 4 months before pioglitazone treatment, macula edema is not present in either eye (A shows the 
right eye, B the left eye). C and D: during pioglitazone, DME is present in both eyes but it is difﬁ  cult to detect in fundus photographs because the DME is very diffuse (C shows 
the right eye, D the left eye).
Abbreviations: DME, diabetic macular edema.Vascular Health and Risk Management 2008:4(5) 1139
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should be carefully monitored. Unfortunately in Japan, some 
physicians prescribing pioglitazone are not aware of the 
development of DME caused by pioglitazone.
One case has been reported that showed that rosiglitazone 
(not available in Japan), a thiazolidinedione agent, was asso-
ciated with vision loss due to DME (Colucciello 2005). In 
that report, the increase of the dosage from 2 to 8 mg/day 
caused the development of DME (Colucciello 2005). In 
our case, the lowest dose (15 mg) of pioglitazone that is 
usually prescribed caused the DME. These ﬁ  ndings suggest 
that individual differences in sensitivity to the glitazones 
may exist.
In a recent retrospective study, a worsening of DME after 
glitazone (pioglitazone and/or rosiglitazone) treatment was 
estimated to be 1.5% and 2.6% of the cases (Ryan et al 2006). 
However, the investigators did not measure the visual 
acuity or evaluate the DME before glitazone treatment. 
Thus, it could not be determined whether their ﬁ  ndings were 
associated with the glitazone treatment or the natural courses 
of diabetic retinopathy.
We followed the protocol for the treatment of ﬂ  uid 
retention and peripheral edema; ﬁ  rst we stopped the use of 
pioglitazone and if there was not a complete resolution of 
the edema, we prescribed one half dose of spironolactone 
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Figure 2 Fluorescein angiograms before and after pioglitazone treatment. A and B: 6 months before pioglitazone treatment, neovascular abnormalities with no leakage are 
present in both maculas but the activity is low and no DME is observed (A shows the right eye, B the left eye). C and D: During pioglitazone treatment, the status of prolif-
erative diabetic retinopathy is not changed before and after pioglitazone treatment. DME is difﬁ  cult to detect in the ﬂ  uorescein angiograms because it is very diffuse. Optical 
coherence tomography shows the diffuse DME more clearly (C shows the right eye, D the left eye).
Abbreviations: DME, diabetic macular edema.
Table 1 Clinical course of systemic condition
Before pioglitazone treatment During pioglitazone treatment After pioglitazone treatment
HbA1c (%) 8–16 (large deviation) 11.1 11.1
Body weight (kg) 65 ± 2 70 62
BUN (mg/dL) 8.0–20.0 12.3 9
Cre (mg/dL) 0.3–0.9 No renal dysfunction 0.39 No renal dysfunction 0.42 No renal dysfunction
Before pioglitazone treatment, HbA1c levels showed large deviation. However, no renal dysfunction has been observed during the follow-up period (4 years). Body weight was 
signiﬁ  cantly increased during pioglitazone treatment.
Abbreviations: BUN; blood urea nitrogen, Cre; creatinine.Vascular Health and Risk Management 2008:4(5) 1140
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(25 mg). Two months after the spironolactone treatment, the 
DME and peripheral edema were signiﬁ  cantly improved.
In conclusion, pioglitazone treatment can lead to the 
development and aggravation of DME and systemic edema 
because of ﬂ  uid retention. Cessation of pioglitazone and 
prescription of one half dose of spironolactone are useful in 
resolving the DME. When a patient taking pioglitazone com-
plains of a decrease of vision, physicians should promptly 
consult an ophthalmologist, and suggest the possibility that 
pioglitazone is causing the same kind of ﬂ  uid retention in 
the macula that it causes systematically.
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Figure 3 OCTs before and after pioglitazone treatment. A: 3 months before 
pioglitazone treatment, macular edema is not present in both eyes. B: 2 weeks after 
pioglitazone, severe diabetic macular edema can be seen in both eyes. C: 6weeks after 
pioglitazone, DME is worse and a serous retinal detachment is present in the right eye. 
D: 2 weeks after cessation of pioglitazone, visual acuity has improved but severe DME 
is still present in the OCT images of the right eye. E: 2 months later after receiving a 
half-dose of spironolactone, DME is signiﬁ  cantly reduced in both eyes.
Abbreviations: DME, diabetic macular edema; OCT, optical coherence tomogram.